Multiple randomized controlled trials and many real-world evidence studies have
consistently shown that non-vitamin K antagonist oral anticoagulants (NOACs) are …

Background: Non–vitamin K antagonist oral anticoagulant (NOAC) drugs are at least
equivalent to warfarin for ischemic stroke prevention in patients with atrial fibrillation and …

Atrial fibrillation (AF) is associated with an increased risk of ischemic stroke or systemic
embolism compared with normal sinus rhythm. These strokes may efficiently be prevented in …

Non-vitamin-K oral anticoagulants (NOACs) represent a major advance in the prevention of
stroke in patients with atrial fibrillation (AF), offering a similar, if not superior, efficacy and …

Worldwide there is a tremendous need for affordable anticoagulants that do not require
monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major …

The prevalence of atrial fibrillation (AF), the most common cardiac arrhythmia, increases with
age, predisposing elderly patients to an increased risk of embolic stroke. With an …

The aims of this article are to review the evidence regarding the use of non-vitamin K oral
anticoagulants (NOACs) for secondary stroke prevention as compared to vitamin K …

Non-Vitamin K antagonist oral anticoagulants (NOACs) have been extensively investigated
in medical conditions at high risk of venous or arterial thrombosis other than atrial fibrillation …

Background and purpose In addition to lowering stroke risk, warfarin use is also associated
with reduced stroke severity in patients with atrial fibrillation and acute ischaemic stroke. It …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …